Physician profile
Mark D Huffman
NPI 1821085457
$12,226.58
in general payments reported to CMS, 2019-2025
23 companies · $915 in 2025
The $915 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $476 · 2021: $1,776 · 2022: $777 · 2023: $1,975 · 2024: $5,349 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,780 · Food and Beverage: $2,250 · Travel and Lodging: $2,183 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,780.00 |
| Food and Beverage | $2,250.09 |
| Travel and Lodging | $2,183.42 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $5,479.44 | 2022-2025 | Cirrus Hd-Oct, Iolmaster 700, Visumax |
| Ivantis, INC | $1,320.23 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $1,277.00 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $1,220.31 | 2019-2025 | Tecnis Iol |
| Glaukos Corporation | $525.18 | 2020-2025 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idosetr |
| Alcon Vision LLC | $512.41 | 2019-2023 | Argos, Luxor |
| Sun Pharmaceutical Industries INC. | $343.89 | 2019-2023 | Cequa |
| Abbvie INC. | $303.77 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $281.85 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.81 | 2019-2021 | |
| Biotissue Holdings INC. | $111.65 | 2019 | |
| Allergan, INC. | $101.86 | 2020 | |
| Ocular Therapeutix, INC. | $100.68 | 2025 | Dextenza |
| Leica Microsystems INC. | $81.86 | 2024 | Surgical Microscopes |
| Horizon Therapeutics Plc | $74.58 | 2021-2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $65.07 | 2021 | |
| Bausch & Lomb Americas INC. | $63.50 | 2024-2025 | Vyzulta, Envista Mx60 Iol |
| Oyster Point Pharma, INC. | $57.86 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $57.45 | 2025 | Acthar |
| Rayner Intraocular Lenses Limited | $35.19 | 2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Novartis Pharmaceuticals Corporation | $31.34 | 2019-2021 | |
| Rxsight INC | $25.59 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Beaver-Visitec International, INC. | $17.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.